The side effects of the vaccine are common but mild. About 50 percent of recipients will report some sort of problem such as redness, pain, swelling, or fever.
There were several cases of Guillain-Barré syndrome (GBS) in the weeks following the administration of Menactra in 2005. However, there is a low background rate of GBS in the general population. It is not clear if those cases were part of the known background rate or due to the Menactra. Based on that information, the CDC is continuing to monitor for any increased risk of GBS after the administration of Menactra.